Melanoma
Conditions
Keywords
melanoma, dendritic cells, apoptotic/necrotic cells, therapeutic vaccine
Brief summary
Background: Sixteen melanoma patients (1 stage IIC, 8 stage III, and 7 stage IV) were treated in a Phase I study to evaluate safety and immune responses, with a vaccine (DC/Apo-Nec) composed of autologous dendritic cells (DCs) loaded with a mixture of apoptotic/necrotic melanoma cell lines (Apo-Nec). Methods: PBMC were obtained from leukapheresis and DCs were generated from monocytes cultured in the presence of GM-CSF and IL-4 in serum-free medium. Immature DCs (iDCs) were loaded with gamma-irradiated Apo-Nec cells and injected id without adjuvant. Cohorts of four patients were given four vaccines with 5, 10, 15, or 20 x106 DC/Apo-Nec per vaccine, two weeks apart. Results: The vaccine was well tolerated in all patients. Toxicity to vaccine was mild, and the toxicity-limiting dose has not been reached. We found that 42.3 ±13.7 % melanoma patients´ iDCs were able to phagocyte Apo-Nec cells wich induced DCs maturation, as evidenced by increased expression of CD83, CD80, CD86, HLA class I and II compared to iDCs. Also, after phagocytosis, a 75.2 ±16 % reduction in Dextran-FITC endocytosis was observed compared to iDCs. CCR7 was upregulated upon Apo-Nec phagocytosis in DCs from all patients and accordingly in vitro DC/Apo-Nec cells were able to migrate towards MIP-3 beta. The DTH score increased significatively in the patients after the first vaccination and slightly decreased by the fourth vaccine (Mann-Whitney Test, p\<0.05). For patient #1 a positive DTH reaction was detected to her own tumor irradiated cells. The presence of CD8+ T lymphocytes specific to gp100 and Melan A/MART-1 Ags were studied by tetramers binding in HLA-A\*0201 patients (7 /15 patients) before and after vaccination. Two patients who remain NED increased Ags their specific T lymphocytes after vaccination. No humoral responses to Apo-Nec cells were detected. With a mean follow-up of 44.5 months post-surgery, the stage IIC pt is NED, 7/8 stage III pts are NED and 7/7 stage IV patients have progressed. Conclussions: We conclude that DC/Apo-Nec vaccine is well tolerated, it induces specific immunity against melanoma Ags and in stage III patients it may prolong disease-free survival, affording protection from relapse in an adjuvant setting.
Interventions
BIOLOGICALDC/Apo-Nec
Sponsors
José Mordoh, M.D., Ph.D.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
17 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* histologically confirmed cutaneous melanoma stages IIB, IIC, III or IV (AJCC) * pts with minimal or non-detectable disease (NED) after surgery as asserted by CAT scans. Melanoma pts with unknown primary tumor site could be included in the study * life expectancy \> 6 months * ages:from 15 to 60 years * performance status (ECOG) 0 or 1 * pts with stage III disease had to be previously treated with IFN-alpha, and either finished the treatment or suspended it due to disease progression, toxicity or other clinical reasons. Alternatively, those pts who had not started IFN-alpha within six months after surgery could be included in this study * a suitable venous access for the leukapheresis procedure * laboratory eligibility criteria included: hemoglobin \> 10 gr %; WBC count \> 4800/mm3, platelets \> 150.000/mm3, total and direct bilirubin, serum oxalacetic transaminase and glutamic pyruvic transaminase \< 1.5 fold the upper normal value; LDH \< 450 mU/ml * absence of pregnancy, with serum βHCG determined one week before vaccination in premenopausal women * serum creatinine \< 1.4 mg % * no chemotherapy, radiotherapy or any biological treatments during the previous month * no concurrent medication with corticosteroids or NSAIDs * l no active brain metastases m- normal ECG * all pts gave written informed consent before inclusion in the Study.
Exclusion criteria
* Ocular melanoma or melanoma of mucosa * Active brain metastases * Other previous carcinoma (with the exeption of cervical or in situ basal cells carcinoma adequately treated) * Pregnant or breast-feeding women * Cardiac Arythmia, severe heart disease. * Bacterial, mycotic or viral serious infections ( \> grade 2 according to NCI common toxicity criteria) * HIV, B or C Hepatitis previous infection * Primary or secondary immunodeficiencies * Other diseases that require treatment with regular corticoids or non steroids anti-inflammatory drugs or COX-2 inhibitors
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Toxicity measured according to the NCI-Common Toxicity Criteria. | 115 days follow up per Subject (Trial duration) |
| Induction of immune responses associated to different vaccine doses | 115 days follow up per subject (Trial duration) |
Secondary
| Measure | Time frame |
|---|---|
| Feasibility | 115 days follow up per subject (Trial duration) |
Countries
Argentina
Outcome results
None listed